Evidence map›Paper›PMID 32989022›Full record

SynthesisGut2020

Recent advances in clinical practice: colorectal cancer chemoprevention in the average-risk population.

Nicolas Chapelle, Myriam Martel, Esther Toes-Zoutendijk, Alan N Barkun, Marc Bardou

Open access · bronzeAbstract readSystematic Review
In one paragraph

Synthesis in Gut, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
4.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 92 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Observational
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 5 countries.

Nicolas ChapelleInstitut des Maladies de l'appareil digestif, Department of Gastroenterology, Hepatology, Nutrition and Medical Oncology, Service de Gastroenterologie, Nantes, France.ORCID 0000-0003-4834-9693
Myriam MartelDepartment of Gastroenterology, McGill University Health Centre, Montreal, Quebec, Canada.
Esther Toes-ZoutendijkPublic Health, Erasmus MC, Rotterdam, The Netherlands.
Alan N BarkunDepartment of Gastroenterology, McGill University Health Centre, Montreal, Quebec, Canada.ORCID 0000-0002-1798-5526
Marc BardouCIC INSERM 1432, CHU Dijon, Dijon, France marc.bardou@u-bourgogne.fr.ORCID 0000-0003-0028-1837
McGill University Health Centre · CACouncil of Independent Colleges · USErasmus MC · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is one of the most common and lethal malignancies in Western countries. Its development is a multistep process that spans more than 15 years, thereby providing an opportunity for prevention and early detection. The high incidence and mortality rates emphasise the need for prevention and screening. Many countries have therefore introduced CRC screening programmes. It is expected, and preliminary evidence in some countries suggests, that this screening effort will decrease CRC-related mortality rates. CRC prevention involves a healthy lifestyle and chemoprevention-more specifically, oral chemoprevention that can interfere with progression from a normal colonic mucosa to adenocarcinoma. This preventive effect is important for individuals with a genetic predisposition, but also in the general population. The ideal chemopreventive agent, or combination of agents, remains unknown, especially when considering safety during long-term use. This review evaluates the evidence across 80 meta-analyses of interventional and observational studies of CRC prevention using medications, vitamins, supplements and dietary factors. This review suggests that the following factors are associated with a decreased incidence of CRC: aspirin, non-steroidal anti-inflammatory drugs, magnesium, folate, a high consumption of fruits and vegetables, fibre and dairy products. An increased incidence of CRC was observed with frequent alcohol or meat consumption. No evidence of a protective effect for tea, coffee, garlic, fish and soy products was found. The level of evidence is moderate for aspirin, β-carotene and selenium, but is low or very low for all other exposures or interventions.

Indexed as

Alcohol DrinkingAlliumAnti-Inflammatory Agents, Non-SteroidalAntioxidantsAspirinCaffeineCoffeeColorectal NeoplasmsDairy ProductsDietary FiberFatty Acids, Omega-3Fish ProductsFolic AcidFruitGarlicGlycine maxAnti-Inflammatory Agents, Non-SteroidalAntioxidantsAspirinCaffeineCoffeeDietary FiberFatty Acids, Omega-3Folic AcidHydroxymethylglutaryl-CoA Reductase InhibitorsMagnesiumTeaVitaminsaspirincancer preventionchemopreventioncolorectal cancervitamins

Identifiers

PMID32989022
PMCPMC7677480
OpenAlexW3091697385

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.